VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder - Markets Insider

Submitted by Anonymous (not verified) on Thu, 04/05/2018 - 12:08

VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive DisorderMarkets Insider"AV-101 has shown very promising results in preclinical antidepressant models, with ketamine-like efficacy, but none of ketamine's side effects," 1 said Mark A. Smith, M.D., Ph.D., Chief Medical Officer of VistaGen Therapeutics. "Building on excellent ...